DOI . ORG {
}
We began analyzing https://link.springer.com/article/10.1007/s40262-018-0679-9, but it redirected us to https://link.springer.com/article/10.1007/s40262-018-0679-9. The analysis below is for the second page.
Title[redir]:
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib | Clinical Pharmacokinetics
Description:
Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is also effective in other plasma cell disorders and non-Hodgkin lymphomas. The main mechanism of action of bortezomib is to inhibit the chymotrypsin-like site of the 20S proteolytic core within the 26S proteasome, thereby inducing cell-cycle arrest and apoptosis. The pharmacokinetic profile of intravenous bortezomib is characterized by a two-compartment model with a rapid initial distribution phase followed by a longer elimination phase and a large volume of distribution. Bortezomib is available for subcutaneous and intravenous administration. Pharmacokinetic studies comparing subcutaneous and intravenous bortezomib demonstrated that systemic exposure was equivalent for both routes; pharmacodynamic parameters of 20S proteasome inhibition were also similar. Renal impairment does not influence the intrinsic pharmacokinetics of bortezomib. However, moderate or severe hepatic impairment causes an increase in plasma concentrations of bortezomib. Therefore, patients with moderate or severe hepatic impairment should start at a reduced dose. Because bortezomib undergoes extensive metabolism by hepatic cytochrome P450 3A4 and 2C19 enzymes, certain strong cytochrome P450 3A4 inducers and inhibitors can also alter the systemic exposure of bortezomib. This article critically reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of bortezomib at various dosing levels and routes of administration as well as in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.
Title[redir]:
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib | Clinical Pharmacokinetics
Description:
Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is also effective in other plasma cell disorders and non-Hodgkin lymphomas. The main mechanism of action of bortezomib is to inhibit the chymotrypsin-like site of the 20S proteolytic core within the 26S proteasome, thereby inducing cell-cycle arrest and apoptosis. The pharmacokinetic profile of intravenous bortezomib is characterized by a two-compartment model with a rapid initial distribution phase followed by a longer elimination phase and a large volume of distribution. Bortezomib is available for subcutaneous and intravenous administration. Pharmacokinetic studies comparing subcutaneous and intravenous bortezomib demonstrated that systemic exposure was equivalent for both routes; pharmacodynamic parameters of 20S proteasome inhibition were also similar. Renal impairment does not influence the intrinsic pharmacokinetics of bortezomib. However, moderate or severe hepatic impairment causes an increase in plasma concentrations of bortezomib. Therefore, patients with moderate or severe hepatic impairment should start at a reduced dose. Because bortezomib undergoes extensive metabolism by hepatic cytochrome P450 3A4 and 2C19 enzymes, certain strong cytochrome P450 3A4 inducers and inhibitors can also alter the systemic exposure of bortezomib. This article critically reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of bortezomib at various dosing levels and routes of administration as well as in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.
Matching Content Categories {📚}
- Education
- Health & Fitness
- Science
Content Management System {📝}
What CMS is doi.org built with?
Custom-built
No common CMS systems were detected on Doi.org, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of doi.org audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Doi.org Make Money? {💸}
We're unsure how the site profits.
Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org has a revenue plan, but it's either invisible or we haven't found it.
Keywords {🔍}
article, google, scholar, pubmed, cas, bortezomib, myeloma, patients, multiple, clin, cancer, proteasome, phase, drug, study, pharmacokinetics, oncol, clinical, inhibitor, therapy, trial, cell, van, blood, dexamethasone, relapsed, httpsdoiorgjco, lymphoma, richardson, httpsdoiorgblood, central, treatment, adams, res, med, advanced, content, research, inhibitors, pharmacokinetic, intravenous, systemic, metabolism, cytochrome, safety, randomized, httpsdoiorg, pharmacol, httpsdoiorgs, amyloidosis,
Topics {✒️}
month download article/chapter tnf-alpha-induced apoptosis autologous stem-cell transplant prolonged progression-free survival san miguel jf relapsed/refractory clonal disease inducing cell-cycle arrest cancer therapy-induced apoptosis androgen-independent prostate cancer national cancer institute potential drug-drug interactions relapsed/refractory multiple myeloma full article pdf transplant-eligible myeloma patients article critically reviews model-based support bortezomib exposure–response relationships related subjects privacy choices/manage cookies pediatric leukemia patients cytochrome p450 reaction received research support population pharmacokinetic analysis saif abdul-majeed van de velde dipeptidyl boronic acids cytochrome p450 enzymes proteasome inhibitor ps-341 cell-cycle progression bortezomib-based therapy drug metab rev drug–drug interactions drug-drug interactions refractory hematologic malignancies european economic area bone marrow microenvironment intracellular protein degradation van der holt potential drug interactions mantle cell lymphoma adverse drug reactions computerised drug database proteasome inhibitor ps341 natl cancer inst randomized controlled trials newly diagnosed myeloma cell cycle control cyp3a inhibitor ketoconazole complete hematologic response de la rubia
Schema {🗺️}
WebPage:
mainEntity:
headline:Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
description:Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is also effective in other plasma cell disorders and non-Hodgkin lymphomas. The main mechanism of action of bortezomib is to inhibit the chymotrypsin-like site of the 20S proteolytic core within the 26S proteasome, thereby inducing cell-cycle arrest and apoptosis. The pharmacokinetic profile of intravenous bortezomib is characterized by a two-compartment model with a rapid initial distribution phase followed by a longer elimination phase and a large volume of distribution. Bortezomib is available for subcutaneous and intravenous administration. Pharmacokinetic studies comparing subcutaneous and intravenous bortezomib demonstrated that systemic exposure was equivalent for both routes; pharmacodynamic parameters of 20S proteasome inhibition were also similar. Renal impairment does not influence the intrinsic pharmacokinetics of bortezomib. However, moderate or severe hepatic impairment causes an increase in plasma concentrations of bortezomib. Therefore, patients with moderate or severe hepatic impairment should start at a reduced dose. Because bortezomib undergoes extensive metabolism by hepatic cytochrome P450 3A4 and 2C19 enzymes, certain strong cytochrome P450 3A4 inducers and inhibitors can also alter the systemic exposure of bortezomib. This article critically reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of bortezomib at various dosing levels and routes of administration as well as in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.
datePublished:2018-05-26T00:00:00Z
dateModified:2018-05-26T00:00:00Z
pageStart:157
pageEnd:168
sameAs:https://doi.org/10.1007/s40262-018-0679-9
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0679-9/MediaObjects/40262_2018_679_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0679-9/MediaObjects/40262_2018_679_Fig2_HTML.png
isPartOf:
name:Clinical Pharmacokinetics
issn:
1179-1926
0312-5963
volumeNumber:58
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Carlyn Rose C. Tan
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Saif Abdul-Majeed
affiliation:
name:Fox Chase Cancer Center
address:
name:Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Brittany Cael
affiliation:
name:Jeanes Hospital
address:
name:Department of Pharmacy, Bone Marrow Transplant Program, Jeanes Hospital, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Stefan K. Barta
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
description:Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is also effective in other plasma cell disorders and non-Hodgkin lymphomas. The main mechanism of action of bortezomib is to inhibit the chymotrypsin-like site of the 20S proteolytic core within the 26S proteasome, thereby inducing cell-cycle arrest and apoptosis. The pharmacokinetic profile of intravenous bortezomib is characterized by a two-compartment model with a rapid initial distribution phase followed by a longer elimination phase and a large volume of distribution. Bortezomib is available for subcutaneous and intravenous administration. Pharmacokinetic studies comparing subcutaneous and intravenous bortezomib demonstrated that systemic exposure was equivalent for both routes; pharmacodynamic parameters of 20S proteasome inhibition were also similar. Renal impairment does not influence the intrinsic pharmacokinetics of bortezomib. However, moderate or severe hepatic impairment causes an increase in plasma concentrations of bortezomib. Therefore, patients with moderate or severe hepatic impairment should start at a reduced dose. Because bortezomib undergoes extensive metabolism by hepatic cytochrome P450 3A4 and 2C19 enzymes, certain strong cytochrome P450 3A4 inducers and inhibitors can also alter the systemic exposure of bortezomib. This article critically reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of bortezomib at various dosing levels and routes of administration as well as in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.
datePublished:2018-05-26T00:00:00Z
dateModified:2018-05-26T00:00:00Z
pageStart:157
pageEnd:168
sameAs:https://doi.org/10.1007/s40262-018-0679-9
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0679-9/MediaObjects/40262_2018_679_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40262-018-0679-9/MediaObjects/40262_2018_679_Fig2_HTML.png
isPartOf:
name:Clinical Pharmacokinetics
issn:
1179-1926
0312-5963
volumeNumber:58
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Carlyn Rose C. Tan
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Saif Abdul-Majeed
affiliation:
name:Fox Chase Cancer Center
address:
name:Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Brittany Cael
affiliation:
name:Jeanes Hospital
address:
name:Department of Pharmacy, Bone Marrow Transplant Program, Jeanes Hospital, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Stefan K. Barta
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Clinical Pharmacokinetics
issn:
1179-1926
0312-5963
volumeNumber:58
Organization:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
name:Fox Chase Cancer Center
address:
name:Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
name:Jeanes Hospital
address:
name:Department of Pharmacy, Bone Marrow Transplant Program, Jeanes Hospital, Philadelphia, USA
type:PostalAddress
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Carlyn Rose C. Tan
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
name:Saif Abdul-Majeed
affiliation:
name:Fox Chase Cancer Center
address:
name:Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
name:Brittany Cael
affiliation:
name:Jeanes Hospital
address:
name:Department of Pharmacy, Bone Marrow Transplant Program, Jeanes Hospital, Philadelphia, USA
type:PostalAddress
type:Organization
name:Stefan K. Barta
affiliation:
name:Fox Chase Cancer Center
address:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
name:Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, USA
name:Department of Pharmacy, Bone Marrow Transplant Program, Jeanes Hospital, Philadelphia, USA
name:Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, USA
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(309)
- How much revenue does https://link.springer.com/privacystatement bring in?
- What's the financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/#main?
- Learn about the earnings of https://link.springer.com
- How much money does https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s40262-018-0679-9 make?
- What's the revenue for https://link.springer.com/article/10.1007/s40262-018-0679-9/#eds-c-header-nav?
- How much does https://link.springer.com/journals/ pull in?
- How much revenue does https://www.springernature.com/gp/authors produce monthly?
- How much does https://link.springernature.com/home/ generate monthly?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/#eds-c-header-popup-search gross monthly?
- What are the earnings of https://order.springer.com/public/cart?
- Check the income stats for https://link.springer.com/article/10.1007/s40262-018-0679-9/
- https://link.springer.com/article/10.1007/s40262-018-0679-9/journal/40262's financial summary
- What's the financial outcome of https://link.springer.com/article/10.1007/s40262-018-0679-9/#citeas?
- Revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/journal/40262/aims-and-scope
- Profit of https://www.editorialmanager.com/cpka/
- https://link.springer.com/article/10.1007/s40262-018-0679-9/#auth-Carlyn_Rose_C_-Tan-Aff1 income
- How much profit does https://link.springer.com/article/10.1007/s40262-018-0679-9/#Aff1 make?
- How profitable is https://link.springer.com/article/10.1007/s40262-018-0679-9/#auth-Saif-Abdul_Majeed-Aff2?
- What's the financial outcome of https://link.springer.com/article/10.1007/s40262-018-0679-9/#Aff2?
- Get to know what's the income of https://link.springer.com/article/10.1007/s40262-018-0679-9/#auth-Brittany-Cael-Aff3
- What's the revenue for https://link.springer.com/article/10.1007/s40262-018-0679-9/#Aff3?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/#auth-Stefan_K_-Barta-Aff1 generate monthly?
- How much profit does https://link.springer.com/article/10.1007/s40262-018-0679-9/article/10.1007/s40262-018-0679-9/metrics make?
- Explore the financials of https://wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40262-018-0679-9
- What's the total monthly financial gain of https://link.springer.com/product/springer-plus?
- How much does https://www.springernature.com/gp/librarians/licensing/agc/journals earn?
- Monthly income for https://link.springer.com/article/10.1007/s40262-018-0679-9/article/10.1007/s40262-018-0679-9#ref-CR35
- How much does https://link.springer.com/10.1208/s12248-020-00448-x?fromPaywallRec=true bring in each month?
- Financial intake of https://link.springer.com/10.1007/s10928-019-09670-3?fromPaywallRec=true
- What's the financial intake of https://link.springer.com/10.1007/s40262-019-00803-y?fromPaywallRec=true?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/biological-therapy rake in every month?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/chemotherapy's total income per month
- What's https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/drug-therapy's gross income?
- How much revenue does https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/pharmacotherapy produce monthly?
- What's the monthly money flow for https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/pharmacokinetics?
- Get to know what's the income of https://link.springer.com/article/10.1007/s40262-018-0679-9/subjects/proteasome
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16518378 pull in monthly?
- How much money does http://scholar.google.com/scholar_lookup?&title=Success%20in%20translational%20research%3A%20lessons%20from%20the%20development%20of%20bortezomib&journal=Nat%20Rev%20Drug%20Discov.&doi=10.1038%2Fnrd1959&volume=5&issue=2&pages=107-114&publication_year=2006&author=S%C3%A1nchez-Serrano%2CI generate?
- What's the financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK1MXjs1ymsbY%3D?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10363983 income
- How much does http://scholar.google.com/scholar_lookup?&title=Proteasome%20inhibitors%3A%20a%20novel%20class%20of%20potent%20and%20effective%20antitumor%20agents&journal=Cancer%20Res.&volume=59&issue=11&pages=2615-2622&publication_year=1999&author=Adams%2CJ&author=Palombella%2CVJ&author=Sausville%2CEA&author=Johnson%2CJ&author=Destree%2CA&author=Lazarus%2CDD earn?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK2sXjtVOrur0%3D rake in every month?
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9165063
- Revenue of http://scholar.google.com/scholar_lookup?&title=New%20insights%20into%20the%20mechanisms%20and%20importance%20of%20the%20proteasome%20in%20intracellular%20protein%20degradation&journal=Biol%20Chem.&volume=378&issue=3%E2%80%934&pages=131-140&publication_year=1997&author=Goldberg%2CAL&author=Akopian%2CTN&author=Kisselev%2CAF&author=Lee%2CDH&author=Rohrwild%2CM
- Learn about the earnings of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK1cXitV2ju7g%3D
- Find out how much http://scholar.google.com/scholar_lookup?&title=The%20ubiquitin-proteasome%20pathway%3A%20the%20complexity%20and%20myriad%20functions%20of%20proteins%20death&journal=Proc%20Natl%20Acad%20Sci%20USA.&doi=10.1073%2Fpnas.95.6.2727&volume=95&issue=6&pages=2727-2730&publication_year=1998&author=Ciechanover%2CA&author=Schwartz%2CAL earns monthly
- What's the income of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK2cXmtVegsLg%3D?
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=The%20ubiquitin-proteasome%20pathway%20is%20required%20for%20processing%20the%20NF-kappa%20B1%20precursor%20protein%20and%20the%20activation%20of%20NF-kappa%20B&journal=Cell.&doi=10.1016%2FS0092-8674%2894%2990482-0&volume=78&issue=5&pages=773-785&publication_year=1994&author=Palombella%2CVJ&author=Rando%2COJ&author=Goldberg%2CAL&author=Maniatis%2CT
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK28XmsFOhu70%3D generate monthly?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=An%20essential%20role%20for%20NF-kappaB%20in%20preventing%20TNF-alpha-induced%20cell%20death&journal=Science.&doi=10.1126%2Fscience.274.5288.782&volume=274&issue=5288&pages=782-784&publication_year=1996&author=Beg%2CAA&author=Baltimore%2CD
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Suppression%20of%20TNF-alpha-induced%20apoptosis%20by%20NF-kappaB&journal=Science.&doi=10.1126%2Fscience.274.5288.787&volume=274&issue=5288&pages=787-789&publication_year=1996&author=Antwerp%2CDJ&author=Martin%2CSJ&author=Kafri%2CT&author=Green%2CDR&author=Verma%2CIM?
- What's the financial outcome of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK28XmsFOhu7Y%3D?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=TNF-%20and%20cancer%20therapy-induced%20apoptosis%3A%20potentiation%20by%20inhibition%20of%20NF-kappaB&journal=Science.&doi=10.1126%2Fscience.274.5288.784&volume=274&issue=5288&pages=784-787&publication_year=1996&author=Wang%2CCY&author=Mayo%2CMW&author=Baldwin%2CAS?
- Discover the revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK1cXhsFKjsr8%3D
- http://scholar.google.com/scholar_lookup?&title=Potent%20and%20selective%20inhibitors%20of%20the%20proteasome%3A%20dipeptidyl%20boronic%20acids&journal=Bioorg%20Med%20Chem%20Lett.&doi=10.1016%2FS0960-894X%2898%2900029-8&volume=8&issue=4&pages=333-338&publication_year=1998&author=Adams%2CJ&author=Behnke%2CM&author=Chen%2CS&author=Cruickshank%2CAA&author=Dick%2CLR&author=Grenier%2CL's financial summary
- Revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2cXksFCmt7s%3D
- What's http://scholar.google.com/scholar_lookup?&title=The%20development%20of%20proteasome%20inhibitors%20as%20anticancer%20drugs&journal=Cancer%20Cell.&doi=10.1016%2FS1535-6108%2804%2900120-5&volume=5&issue=5&pages=417-421&publication_year=2004&author=Adams%2CJ's gross income?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK2sXnvFGjsLc%3D bring in each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Roles%20of%20ubiquitin-mediated%20proteolysis%20in%20cell%20cycle%20control&journal=Curr%20Opin%20Cell%20Biol.&doi=10.1016%2FS0955-0674%2897%2980079-8&volume=9&issue=6&pages=788-799&publication_year=1997&author=Hershko%2CA pull in monthly?
- How much revenue does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK1cXjtFWqsr4%3D generate?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9600100
- How much profit does http://scholar.google.com/scholar_lookup?&title=The%20proteasome%20is%20involved%20in%20angiogenesis&journal=Biochem%20Biophys%20Res%20Commun.&doi=10.1006%2Fbbrc.1998.8604&volume=246&issue=1&pages=243-248&publication_year=1998&author=Oikawa%2CT&author=Sasaki%2CT&author=Nakamura%2CM&author=Shimamura%2CM&author=Tanahashi%2CN&author=Omura%2CS generate?
- What's the financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK3sXmtVSks7Y%3D?
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8400144 makes per month
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Adhesion%20molecules%20in%20tumor%20metastasis&journal=Semin%20Cancer%20Biol.&volume=4&issue=4&pages=219-229&publication_year=1993&author=Zetter%2CBR
- What's the financial intake of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK2MXlvVWrsLk%3D?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=The%20proteasome%20pathway%20is%20required%20for%20cytokine-induced%20endothelial-leukocyte%20adhesion%20molecule%20expression&journal=Immunity.&doi=10.1016%2F1074-7613%2895%2990030-6&volume=2&issue=5&pages=493-506&publication_year=1995&author=Read%2CMA&author=Neish%2CAS&author=Luscinskas%2CFW&author=Palombella%2CVJ&author=Maniatis%2CT&author=Collins%2CT?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD3MXivFGqsL0%3D's revenue stream
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11306489
- Find out how much http://scholar.google.com/scholar_lookup?&title=The%20proteasome%20inhibitor%20PS-341%20inhibits%20growth%2C%20induces%20apoptosis%2C%20and%20overcomes%20drug%20resistance%20in%20human%20multiple%20myeloma%20cells&journal=Cancer%20Res.&volume=61&issue=7&pages=3071-3076&publication_year=2001&author=Hideshima%2CT&author=Richardson%2CP&author=Chauhan%2CD&author=Palombella%2CVJ&author=Elliott%2CPJ&author=Adams%2CJ earns monthly
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD3sXht1ansr4%3D net monthly?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12393500 income
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Molecular%20mechanisms%20mediating%20antimyeloma%20activity%20of%20proteasome%20inhibitor%20PS-341&journal=Blood.&doi=10.1182%2Fblood-2002-08-2543&volume=101&issue=4&pages=1530-1534&publication_year=2003&author=Hideshima%2CT&author=Mitsiades%2CC&author=Akiyama%2CM&author=Hayashi%2CT&author=Chauhan%2CD&author=Richardson%2CP?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2MXltlaksLc%3D generate monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15958804 gross monthly?
- http://scholar.google.com/scholar_lookup?&title=Bortezomib%20or%20high-dose%20dexamethasone%20for%20relapsed%20multiple%20myeloma&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa043445&volume=352&issue=24&pages=2487-2498&publication_year=2005&author=Richardson%2CPG&author=Sonneveld%2CP&author=Schuster%2CMW&author=Irwin%2CD&author=Stadtmauer%2CEA&author=Facon%2CT income
- Discover the revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtVGms77K
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18753647
- How much does http://scholar.google.com/scholar_lookup?&title=Bortezomib%20plus%20melphalan%20and%20prednisone%20for%20initial%20treatment%20of%20multiple%20myeloma&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa0801479&volume=359&issue=9&pages=906-917&publication_year=2008&author=San%20Miguel%2CJF&author=Schlag%2CR&author=Khuageva%2CNK&author=Dimopoulos%2CMA&author=Shpilberg%2CO&author=Kropff%2CM gross monthly?
- Profit of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38XhtlalurbE
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22791289 income
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Superiority%20of%20bortezomib%2C%20thalidomide%2C%20and%20dexamethasone%20%28VTD%29%20as%20induction%20pretransplantation%20therapy%20in%20multiple%20myeloma%3A%20a%20randomized%20phase%203%20PETHEMA%2FGEM%20study&journal=Blood.&doi=10.1182%2Fblood-2012-02-408922&volume=120&issue=8&pages=1589-1596&publication_year=2012&author=Rosi%C3%B1ol%2CL&author=Oriol%2CA&author=Teruel%2CAI&author=Hern%C3%A1ndez%2CD&author=L%C3%B3pez-Jim%C3%A9nez%2CJ&author=Rubia%2CJ?
- How much revenue does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks7%2FK bring in?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27557302's gross income?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Daratumumab%2C%20bortezomib%2C%20and%20dexamethasone%20for%20multiple%20myeloma&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1606038&volume=375&issue=8&pages=754-766&publication_year=2016&author=Palumbo%2CA&author=Chanan-Khan%2CA&author=Weisel%2CK&author=Nooka%2CAK&author=Masszi%2CT&author=Beksac%2CM
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC28XitFGitbbO pull in?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28017406
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Bortezomib%20with%20lenalidomide%20and%20dexamethasone%20versus%20lenalidomide%20and%20dexamethasone%20alone%20in%20patients%20with%20newly%20diagnosed%20myeloma%20without%20intent%20for%20immediate%20autologous%20stem-cell%20transplant%20%28SWOG%20S0777%29%3A%20a%20randomised%2C%20open-label%2C%20phase%203%20trial&journal=Lancet.&doi=10.1016%2FS0140-6736%2816%2931594-X&volume=389&issue=10068&pages=519-527&publication_year=2017&author=Durie%2CBG&author=Hoering%2CA&author=Abidi%2CMH&author=Rajkumar%2CSV&author=Epstein%2CJ&author=Kahanic%2CSP
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtlarur3K's financial summary
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17690257's revenue stream
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Extended%20follow-up%20of%20a%20phase%203%20trial%20in%20relapsed%20multiple%20myeloma%3A%20final%20time-to-event%20results%20of%20the%20APEX%20trial&journal=Blood.&doi=10.1182%2Fblood-2006-08-036947&volume=110&issue=10&pages=3557-3560&publication_year=2007&author=Richardson%2CPG&author=Sonneveld%2CP&author=Schuster%2CM&author=Irwin%2CD&author=Stadtmauer%2CE&author=Facon%2CT produce monthly?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslGgt7jI income
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25263936's total income per month
- How much profit is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856151 making per month?
- Get to know http://scholar.google.com/scholar_lookup?&title=Bortezomib%20for%20the%20treatment%20of%20non-Hodgkin%E2%80%99s%20lymphoma&journal=Expert%20Opin%20Pharmacother.&doi=10.1517%2F14656566.2014.965142&volume=15&issue=16&pages=2443-2459&publication_year=2014&author=Bose%2CP&author=Batalo%2CMS&author=Holkova%2CB&author=Grant%2CS's earnings
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38Xht1Srur7L's total income per month
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22645181 generate?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123429 pull in monthly?
- How much money does http://scholar.google.com/scholar_lookup?&title=Proteasome%20inhibitors%20in%20multiple%20myeloma%3A%2010%C2%A0years%20later&journal=Blood.&doi=10.1182%2Fblood-2012-04-403733&volume=120&issue=5&pages=947-959&publication_year=2012&author=Moreau%2CP&author=Richardson%2CPG&author=Cavo%2CM&author=Orlowski%2CRZ&author=San%20Miguel%2CJF&author=Palumbo%2CA make?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27096326 bring in each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Bortezomib%20for%20the%20treatment%20of%20multiple%20myeloma&journal=Cochrane%20Database%20Syst%20Rev.&doi=10.1002%2F14651858.cd010816.pub2&volume=4&publication_year=2016&author=Scott%2CK&author=Hayden%2CPJ&author=Will%2CA&author=Wheatley%2CK&author=Coyne%2CI net monthly?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21507715
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Subcutaneous%20versus%20intravenous%20administration%20of%20bortezomib%20in%20patients%20with%20relapsed%20multiple%20myeloma%3A%20a%20randomised%2C%20phase%203%2C%20non-inferiority%20study&journal=Lancet%20Oncol.&doi=10.1016%2FS1470-2045%2811%2970081-X&volume=12&issue=5&pages=431-440&publication_year=2011&author=Moreau%2CP&author=Pylypenko%2CH&author=Grosicki%2CS&author=Karamanesht%2CI&author=Leleu%2CX&author=Grishunina%2CM is on a monthly basis
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DyaK1MXmsFyjtro%3D earn?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10499643 pull in?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=The%20proteasome%20inhibitor%20PS-341%20in%20cancer%20therapy&journal=Clin%20Cancer%20Res.&volume=5&issue=9&pages=2638-2645&publication_year=1999&author=Teicher%2CBA&author=Ara%2CG&author=Herbst%2CR&author=Palombella%2CVJ&author=Adams%2CJ
- Discover the revenue of https://link.springer.com/doi/10.1007/s00280-011-1637-5
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsVyrt73L make?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21479634 earning monthly?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481841 generate monthly?
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Dose-escalating%20and%20pharmacological%20study%20of%20bortezomib%20in%20adult%20cancer%20patients%20with%20impaired%20renal%20function%3A%20a%20National%20Cancer%20Institute%20Organ%20Dysfunction%20Working%20Group%20Study&journal=Cancer%20Chemother%20Pharmacol.&doi=10.1007%2Fs00280-011-1637-5&volume=68&issue=6&pages=1439-1447&publication_year=2011&author=Leal%2CTB&author=Remick%2CSC&author=Takimoto%2CCH&author=Ramanathan%2CRK&author=Davies%2CA&author=Egorin%2CMJ?
- What's the total monthly financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38Xnt1Cjsbk%3D?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22394984?
- http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20and%20safety%20of%20bortezomib%20in%20patients%20with%20advanced%20malignancies%20and%20varying%20degrees%20of%20liver%20dysfunction%3A%20phase%20I%20NCI%20Organ%20Dysfunction%20Working%20Group%20Study%20NCI-6432&journal=Clin%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-11-2873&volume=18&issue=10&pages=2954-2963&publication_year=2012&author=LoRusso%2CPM&author=Venkatakrishnan%2CK&author=Ramanathan%2CRK&author=Sarantopoulos%2CJ&author=Mulkerin%2CD&author=Shibata%2CSI income
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2cXpsVWlsLc%3D's revenue stream
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15169797?
- http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%20the%20proteasome%20inhibitor%20bortezomib%20in%20patients%20with%20advanced%20solid%20tumors%20with%20observations%20in%20androgen-independent%20prostate%20cancer&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2004.02.106&volume=22&issue=11&pages=2108-2121&publication_year=2004&author=Papandreou%2CCN&author=Daliani%2CDD&author=Nix%2CD&author=Yang%2CH&author=Madden%2CT&author=Wang%2CX income
- Earnings of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtFynur4%3D
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18768528 make?
- See how much http://scholar.google.com/scholar_lookup?&title=Prospective%20comparison%20of%20subcutaneous%20versus%20intravenous%20administration%20of%20bortezomib%20in%20patients%20with%20multiple%20myeloma&journal=Haematologica.&doi=10.3324%2Fhaematol.13285&volume=93&issue=12&pages=1908-1911&publication_year=2008&author=Moreau%2CP&author=Coiteux%2CV&author=Hulin%2CC&author=Leleu%2CX&author=Velde%2CH&author=Acharya%2CM makes per month
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15688598 income
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Pharmacology%2C%20pharmacokinetics%2C%20and%20practical%20applications%20of%20bortezomib&journal=Oncology%20%28Williston%20Park%29.&volume=18&issue=14%20Suppl.%2011&pages=14-21&publication_year=2004&author=Schwartz%2CR&author=Davidson%2CT?
- What are the earnings of https://link.springer.com/doi/10.1007/s00280-010-1283-3?
- What's the monthly money flow for https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXpvFWr?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20306195?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic%20and%20pharmacodynamic%20study%20of%20two%20doses%20of%20bortezomib%20in%20patients%20with%20relapsed%20multiple%20myeloma&journal=Cancer%20Chemother%20Pharmacol.&doi=10.1007%2Fs00280-010-1283-3&volume=67&issue=1&pages=57-67&publication_year=2011&author=Reece%2CDE&author=Sullivan%2CD&author=Lonial%2CS&author=Mohrbacher%2CAF&author=Chatta%2CG&author=Shustik%2CC?
- Income figures for https://link.springer.com/doi/10.1007/s40262-012-0010-0
- Profit of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsFemtrs%3D
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23018466
- http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic%2C%20pharmacodynamic%20and%20covariate%20analysis%20of%20subcutaneous%20versus%20intravenous%20administration%20of%20bortezomib%20in%20patients%20with%20relapsed%20multiple%20myeloma&journal=Clin%20Pharmacokinet.&doi=10.1007%2Fs40262-012-0010-0&volume=51&issue=12&pages=823-829&publication_year=2012&author=Moreau%2CP&author=Karamanesht%2CII&author=Domnikova%2CN&author=Kyselyova%2CMY&author=Vilchevska%2CKV&author=Doronin%2CVA's total income per month
- Profit of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD28XivVChtLs%3D
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16608165 net monthly?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Oxidative%20deboronation%20of%20the%20peptide%20boronic%20acid%20proteasome%20inhibitor%20bortezomib%3A%20contributions%20from%20reactive%20oxygen%20species%20in%20this%20novel%20cytochrome%20P450%20reaction&journal=Chem%20Res%20Toxicol.&doi=10.1021%2Ftx050313d&volume=19&issue=4&pages=539-546&publication_year=2006&author=Labutti%2CJ&author=Parsons%2CI&author=Huang%2CR&author=Miwa%2CG&author=Gan%2CLS&author=Daniels%2CJS earns monthly
- Explore the financials of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2MXksleksrg%3D
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15764713 makes per month
- How much does http://scholar.google.com/scholar_lookup?&title=Human%20metabolism%20of%20the%20proteasome%20inhibitor%20bortezomib%3A%20identification%20of%20circulating%20metabolites&journal=Drug%20Metab%20Dispos.&doi=10.1124%2Fdmd.104.002956&volume=33&issue=6&pages=771-777&publication_year=2005&author=Pekol%2CT&author=Daniels%2CJS&author=Labutti%2CJ&author=Parsons%2CI&author=Nix%2CD&author=Baronas%2CE bring in each month?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtFOru7rP make?
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16103134
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Relative%20contributions%20of%20the%20five%20major%20human%20cytochromes%20P450%2C%201A2%2C%202C9%2C%202C19%2C%202D6%2C%20and%203A4%2C%20to%20the%20hepatic%20metabolism%20of%20the%20proteasome%20inhibitor%20bortezomib&journal=Drug%20Metab%20Dispos.&doi=10.1124%2Fdmd.105.005710&volume=33&issue=11&pages=1723-1728&publication_year=2005&author=Uttamsingh%2CV&author=Lu%2CC&author=Miwa%2CG&author=Gan%2CLS each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Drug-drug%20interactions%20in%20medical%20patients%3A%20effects%20of%20in-hospital%20treatment%20and%20relation%20to%20multiple%20drug%20use&journal=Int%20J%20Clin%20Pharmacol%20Ther.&doi=10.5414%2FCPP38504&volume=38&issue=11&pages=504-513&publication_year=2000&author=K%C3%B6hler%2CGI&author=Bode-B%C3%B6ger%2CSM&author=Busse%2CR&author=Hoopmann%2CM&author=Welte%2CT&author=B%C3%B6ger%2CRH earn?
- What's the profit of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD3sXntlCiu7w%3D?
- How much does http://scholar.google.com/scholar_lookup?&title=Identification%20of%20adverse%20drug%20reactions%20in%20geriatric%20inpatients%20using%20a%20computerised%20drug%20database&journal=Drugs%20Aging.&doi=10.2165%2F00002512-200320100-00005&volume=20&issue=10&pages=769-776&publication_year=2003&author=Egger%2CT&author=Dormann%2CH&author=Ahne%2CG&author=Runge%2CU&author=Neubert%2CA&author=Criegee-Rieck%2CM bring in each month?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:STN:280:DC%2BD2s7otFOnsA%3D%3D rake in every month?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17381667's gross income?
- Income figures for http://scholar.google.com/scholar_lookup?&title=Polypharmacy%20in%20older%20oncology%20patients%20and%20the%20need%20for%20an%20interdisciplinary%20approach%20to%20side-effect%20management&journal=J%20Clin%20Pharm%20Ther.&doi=10.1111%2Fj.1365-2710.2007.00815.x&volume=32&issue=2&pages=169-175&publication_year=2007&author=Sokol%2CKC&author=Knudsen%2CJF&author=Li%2CMM
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:STN:280:DC%2BD3Mrlt1CitA%3D%3D rake in every month?
- How much does http://scholar.google.com/scholar_lookup?&title=Fatal%20adverse%20drug%20events%3A%20the%20paradox%20of%20drug%20treatment&journal=J%20Intern%20Med.&doi=10.1046%2Fj.1365-2796.2001.00892.x&volume=250&issue=4&pages=327-341&publication_year=2001&author=Buajordet%2CI&author=Ebbesen%2CJ&author=Erikssen%2CJ&author=Br%C3%B8rs%2CO&author=Hilberg%2CT pull in monthly?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXksVKku78%3D's revenue stream
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23412102
- Profit of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619066
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20potential%20drug-drug%20interactions%20in%20cancer%20patients%20treated%20with%20oral%20anticancer%20drugs&journal=Br%20J%20Cancer.&doi=10.1038%2Fbjc.2013.48&volume=108&issue=5&pages=1071-1078&publication_year=2013&author=Leeuwen%2CRW&author=Brundel%2CDH&author=Neef%2CC&author=Gelder%2CT&author=Mathijssen%2CRH&author=Burger%2CDM
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17440160 earning monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Potential%20drug%20interactions%20and%20duplicate%20prescriptions%20among%20cancer%20patients&journal=J%20Natl%20Cancer%20Inst.&doi=10.1093%2Fjnci%2Fdjk130&volume=99&issue=8&pages=592-600&publication_year=2007&author=Riechelmann%2CRP&author=Tannock%2CIF&author=Wang%2CL&author=Saad%2CED&author=Taback%2CNA&author=Krzyzanowska%2CMK generate monthly?
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21343376 making per month?
- Profit of http://scholar.google.com/scholar_lookup?&title=Potential%20drug%20interactions%20in%20cancer%20therapy%3A%20a%20prevalence%20study%20using%20an%20advanced%20screening%20method&journal=Ann%20Oncol.&doi=10.1093%2Fannonc%2Fmdq761&volume=22&issue=10&pages=2334-2341&publication_year=2011&author=Leeuwen%2CRW&author=Swart%2CEL&author=Boven%2CE&author=Boom%2CFA&author=Schuitenmaker%2CMG&author=Hugtenburg%2CJG
- Income figures for https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXislykt7w%3D
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23333322 making per month?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Cytochrome%20P450%20enzymes%20in%20drug%20metabolism%3A%20regulation%20of%20gene%20expression%2C%20enzyme%20activities%2C%20and%20impact%20of%20genetic%20variation&journal=Pharmacol%20Ther.&doi=10.1016%2Fj.pharmthera.2012.12.007&volume=138&issue=1&pages=103-141&publication_year=2013&author=Zanger%2CUM&author=Schwab%2CM?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3cXoslKjtg%3D%3D's financial summary
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20110052 make?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Effect%20of%20the%20CYP3A%20inhibitor%20ketoconazole%20on%20the%20pharmacokinetics%20and%20pharmacodynamics%20of%20bortezomib%20in%20patients%20with%20advanced%20solid%20tumors%3A%20a%20prospective%2C%20multicenter%2C%20open-label%2C%20randomized%2C%20two-way%20crossover%20drug%E2%80%93drug%20interaction%20study&journal=Clin%20Ther.&doi=10.1016%2Fj.clinthera.2009.11.012&volume=31&issue=Pt%202&pages=2444-2458&publication_year=2009&author=Venkatakrishnan%2CK&author=Rader%2CM&author=Ramanathan%2CRK&author=Ramalingam%2CS&author=Chen%2CE&author=Riordan%2CW
- What's the financial intake of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXmtlantLk%3D?
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19385713?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Effect%20of%20the%20cytochrome%20P450%202C19%20inhibitor%20omeprazole%20on%20the%20pharmacokinetics%20and%20safety%20profile%20of%20bortezomib%20in%20patients%20with%20advanced%20solid%20tumours%2C%20non-Hodgkin%E2%80%99s%20lymphoma%20or%20multiple%20myeloma&journal=Clin%20Pharmacokinet.&doi=10.2165%2F00003088-200948030-00006&volume=48&issue=3&pages=199-209&publication_year=2009&author=Quinn%2CDI&author=Nemunaitis%2CJ&author=Fuloria%2CJ&author=Britten%2CCD&author=Gabrail%2CN&author=Yee%2CL?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38XjsF2kt78%3D pull in monthly?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22087865 earning monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Effect%20of%20cytochrome%20P450%203A4%20inducers%20on%20the%20pharmacokinetic%2C%20pharmacodynamic%20and%20safety%20profiles%20of%20bortezomib%20in%20patients%20with%20multiple%20myeloma%20or%20non-Hodgkin%E2%80%99s%20lymphoma&journal=Clin%20Pharmacokinet.&doi=10.2165%2F11594410-000000000-00000&volume=50&issue=12&pages=781-791&publication_year=2011&author=Hellmann%2CA&author=Rule%2CS&author=Walewski%2CJ&author=Shpilberg%2CO&author=Feng%2CH&author=Velde%2CH bring in?
- What are the total earnings of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvFWhsb3L?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26397802 make?
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Patterns%20and%20effectiveness%20of%20bortezomib%20use%20according%20to%20age%20in%20the%20VESUVE%20cohort&journal=Leuk%20Lymphoma.&doi=10.3109%2F10428194.2015.1096354&volume=57&issue=6&pages=1349-1354&publication_year=2016&author=Grelaud%2CA&author=Fourrier-R%C3%A9glat%2CA&author=Fitoussi%2CO&author=Facon%2CT&author=Jov%C3%A9%2CJ&author=B%C3%A9nichou%2CJ
- What is the monthly revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC2MXht1emtr%2FF?
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26103436?
- How much profit does http://scholar.google.com/scholar_lookup?&title=Mantle%20cell%20lymphoma%3A%202015%20update%20on%20diagnosis%2C%20risk-stratification%2C%20and%20clinical%20management&journal=Am%20J%20Hematol.&doi=10.1002%2Fajh.24094&volume=90&issue=8&pages=739-745&publication_year=2015&author=Vose%2CJM make?
- What's the financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2cXotlOjtA%3D%3D?
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Age-related%20changes%20in%20pharmacokinetics%20and%20pharmacodynamics%3A%20basic%20principles%20and%20practical%20applications&journal=Br%20J%20Clin%20Pharmacol.&doi=10.1046%2Fj.1365-2125.2003.02007.x&volume=57&issue=1&pages=6-14&publication_year=2004&author=Mangoni%2CAA&author=Jackson%2CSH?
- Get to know what's the income of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXnsVagsrc%3D
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19514965
- See how much http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20and%20drug%20metabolism%20in%20the%20elderly&journal=Drug%20Metab%20Rev.&doi=10.1080%2F03602530902722679&volume=41&issue=2&pages=67-76&publication_year=2009&author=Klotz%2CU makes per month
- Get to know https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsVGqu7rO's earnings
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21841166 earning monthly?
- http://scholar.google.com/scholar_lookup?&title=Personalized%20therapy%20in%20multiple%20myeloma%20according%20to%20patient%20age%20and%20vulnerability%3A%20a%20report%20of%20the%20European%20Myeloma%20Network%20%28EMN%29&journal=Blood.&doi=10.1182%2Fblood-2011-06-358812&volume=118&issue=17&pages=4519-4529&publication_year=2011&author=Palumbo%2CA&author=Bringhen%2CS&author=Ludwig%2CH&author=Dimopoulos%2CMA&author=Blad%C3%A9%2CJ&author=Mateos%2CMV's financial summary
- How much revenue does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlemt73I produce monthly?
- How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28419486 have monthly?
- What are the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561493?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Population%20pharmacokinetic%20analysis%20of%20bortezomib%20in%20pediatric%20leukemia%20patients%3A%20model-based%20support%20for%20body%20surface%20area-based%20dosing%20over%20the%202-%20to%2016-year%20age%20range&journal=J%20Clin%20Pharmacol.&doi=10.1002%2Fjcph.906&volume=57&issue=9&pages=1183-1193&publication_year=2017&author=Hanley%2CMJ&author=Mould%2CDR&author=Taylor%2CTJ&author=Gupta%2CN&author=Suryanarayan%2CK&author=Neuwirth%2CR?
- See how much https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38XovVylur8%3D makes per month
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22448619?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Impact%20of%20obesity%20on%20drug%20metabolism%20and%20elimination%20in%20adults%20and%20children&journal=Clin%20Pharmacokinet.&doi=10.2165%2F11599410-000000000-00000&volume=51&issue=5&pages=277-304&publication_year=2012&author=Brill%2CMJ&author=Diepstraten%2CJ&author=Rongen%2CA&author=Kralingen%2CS&author=Anker%2CJN&author=Knibbe%2CCA
- What is the monthly revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD3cXjsVKksb0%3D?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10794750 make?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Proteasome%20inhibition%20measurements%3A%20clinical%20application&journal=Clin%20Chem.&volume=46&issue=5&pages=673-683&publication_year=2000&author=Lightcap%2CES&author=McCormack%2CTA&author=Pien%2CCS&author=Chau%2CV&author=Adams%2CJ&author=Elliott%2CPJ
- Discover the revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD38XmvVaiu7g%3D
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12171876
- See how much http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%20trial%20of%20the%20novel%20proteasome%20inhibitor%20PS341%20in%20advanced%20solid%20tumor%20malignancies&journal=Clin%20Cancer%20Res.&volume=8&issue=8&pages=2505-2511&publication_year=2002&author=Aghajanian%2CC&author=Soignet%2CS&author=Dizon%2CDS&author=Pien%2CCS&author=Adams%2CJ&author=Elliott%2CPJ makes per month
- How much profit is https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD38XosFCjs70%3D making per month?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12431963 bring in each month?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%20the%20proteasome%20inhibitor%20PS-341%20in%20patients%20with%20refractory%20hematologic%20malignancies&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2002.01.133&volume=20&issue=22&pages=4420-4427&publication_year=2002&author=Orlowski%2CRZ&author=Stinchcombe%2CTE&author=Mitchell%2CBS&author=Shea%2CTC&author=Baldwin%2CAS&author=Stahl%2CS?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2cXpvFait7g%3D gross monthly?
- What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15461622?
- How much income is http://scholar.google.com/scholar_lookup?&title=A%20phase%202%20study%20of%20two%20doses%20of%20bortezomib%20in%20relapsed%20or%20refractory%20myeloma&journal=Br%20J%20Haematol.&doi=10.1111%2Fj.1365-2141.2004.05188.x&volume=127&issue=2&pages=165-172&publication_year=2004&author=Jagannath%2CS&author=Barlogie%2CB&author=Berenson%2CJ&author=Siegel%2CD&author=Irwin%2CD&author=Richardson%2CPG earning monthly?
- What's the financial gain of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD3sXkvVSksLs%3D?
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12826635
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=A%20phase%202%20study%20of%20bortezomib%20in%20relapsed%2C%20refractory%20myeloma&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa030288&volume=348&issue=26&pages=2609-2617&publication_year=2003&author=Richardson%2CPG&author=Barlogie%2CB&author=Berenson%2CJ&author=Singhal%2CS&author=Jagannath%2CS&author=Irwin%2CD?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3cXpsFSgt7s%3D net monthly?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20368561 generate?
- How much does http://scholar.google.com/scholar_lookup?&title=Bortezomib%20plus%20melphalan%20and%20prednisone%20compared%20with%20melphalan%20and%20prednisone%20in%20previously%20untreated%20multiple%20myeloma%3A%20updated%20follow-up%20and%20impact%20of%20subsequent%20therapy%20in%20the%20phase%20III%20VISTA%20trial&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2009.26.0638&volume=28&issue=13&pages=2259-2266&publication_year=2010&author=Mateos%2CMV&author=Richardson%2CPG&author=Schlag%2CR&author=Khuageva%2CNK&author=Dimopoulos%2CMA&author=Shpilberg%2CO net monthly?
- Explore the financials of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFCnu7k%3D
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29296961 makes per month
- How much income does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738982 have?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Network%20meta-analysis%20of%20randomized%20trials%20in%20multiple%20myeloma%3A%20efficacy%20and%20safety%20in%20relapsed%2Frefractory%20patients&journal=Blood%20Adv.&doi=10.1182%2Fbloodadvances.2016003905&volume=1&issue=7&pages=455-466&publication_year=2017&author=Botta%2CC&author=Ciliberto%2CD&author=Rossi%2CM&author=Staropoli%2CN&author=Cuc%C3%A8%2CM&author=Galeano%2CT
- What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28977957?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617517?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Meta-analysis%20of%20the%20efficacy%20of%20treatments%20for%20newly%20diagnosed%20and%20relapsed%2Frefractory%20multiple%20myeloma%20with%20del%2817p%29&journal=Oncotarget.&doi=10.18632%2Foncotarget.18722&volume=8&issue=37&pages=62435-62444&publication_year=2017&author=Liu%2CJ&author=Yang%2CH&author=Liang%2CX&author=Wang%2CY&author=Hou%2CJ&author=Liu%2CY?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvVSht7vN earn?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24005889
- How much does http://scholar.google.com/scholar_lookup?&title=Bortezomib-containing%20induction%20regimens%20in%20transplant-eligible%20myeloma%20patients%3A%20a%20meta-analysis%20of%20phase%203%20randomized%20clinical%20trials&journal=Cancer.&doi=10.1002%2Fcncr.28325&volume=119&issue=23&pages=4119-4128&publication_year=2013&author=Nooka%2CAK&author=Kaufman%2CJL&author=Behera%2CM&author=Langston%2CA&author=Waller%2CEK&author=Flowers%2CCR pull in?
- What's the monthly money flow for https://link.springer.com/doi/10.1007/s00277-013-1711-7?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXptFKjur4%3D income
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23455401 income
- Profit of http://scholar.google.com/scholar_lookup?&title=Bortezomib%20for%20patients%20with%20previously%20untreated%20multiple%20myeloma%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&journal=Ann%20Hematol.&doi=10.1007%2Fs00277-013-1711-7&volume=92&issue=7&pages=935-943&publication_year=2013&author=Zeng%2CZ&author=Lin%2CJ&author=Chen%2CJ
- How much revenue does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38XhsFertrfF bring in?
- What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22802322?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Bortezomib%20induction%20and%20maintenance%20treatment%20in%20patients%20with%20newly%20diagnosed%20multiple%20myeloma%3A%20results%20of%20the%20randomized%20phase%20III%20HOVON-65%2F%20GMMG-HD4%20trial&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2011.39.6820&volume=30&issue=24&pages=2946-2955&publication_year=2012&author=Sonneveld%2CP&author=Schmidt-Wolf%2CIG&author=Holt%2CB&author=Jarari%2CL&author=Bertsch%2CU&author=Salwender%2CH?
- Discover the revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVylsbfL
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26056177 makes per month
- How much does http://scholar.google.com/scholar_lookup?&title=Community-based%20phase%20IIIB%20trial%20of%20three%20UPFRONT%20bortezomib-based%20myeloma%20regimens&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2014.58.7618&volume=33&issue=33&pages=3921-3929&publication_year=2015&author=Niesvizky%2CR&author=Flinn%2CIW&author=Rifkin%2CR&author=Gabrail%2CN&author=Charu%2CV&author=Clowney%2CB earn?
- What are the total earnings of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC2MXlt1Gru7c%3D?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25738670
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Bortezomib-based%20therapy%20for%20newly%20diagnosed%20mantle-cell%20lymphoma&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1412096&volume=372&issue=10&pages=944-953&publication_year=2015&author=Robak%2CT&author=Huang%2CH&author=Jin%2CJ&author=Zhu%2CJ&author=Liu%2CT&author=Samoilova%2CO?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17001068 bring in?
- How much does http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20II%20study%20of%20bortezomib%20in%20patients%20with%20relapsed%20or%20refractory%20mantle%20cell%20lymphoma&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2006.07.9665&volume=24&issue=30&pages=4867-4874&publication_year=2006&author=Fisher%2CRI&author=Bernstein%2CSH&author=Kahl%2CBS&author=Djulbegovic%2CB&author=Robertson%2CMJ&author=Vos%2CS generate monthly?
- Financial intake of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:STN:280:DC%2BD1M7mvVWquw%3D%3D
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19074748 make?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Bortezomib%20in%20patients%20with%20relapsed%20or%20refractory%20mantle%20cell%20lymphoma%3A%20updated%20time-to-event%20analyses%20of%20the%20multicenter%20phase%202%20PINNACLE%20study&journal=Ann%20Oncol.&doi=10.1093%2Fannonc%2Fmdn656&volume=20&issue=3&pages=520-525&publication_year=2009&author=Goy%2CA&author=Bernstein%2CSH&author=Kahl%2CBS&author=Djulbegovic%2CB&author=Robertson%2CMJ&author=Vos%2CS?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3cXktF2ltrY%3D's revenue stream
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20085941 generate?
- http://scholar.google.com/scholar_lookup?&title=Bortezomib%20with%20or%20without%20dexamethasone%20in%20primary%20systemic%20%28light%20chain%29%20amyloidosis&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2009.23.8220&volume=28&issue=6&pages=1031-1037&publication_year=2010&author=Kastritis%2CE&author=Wechalekar%2CAD&author=Dimopoulos%2CMA&author=Merlini%2CG&author=Hawkins%2CPN&author=Perfetti%2CV income
- How much cash flow does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVSiu7zF have monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18245653 pull in?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20bortezomib%20in%20systemic%20AL%20amyloidosis%20with%20relapsed%2Frefractory%20clonal%20disease&journal=Haematologica.&doi=10.3324%2Fhaematol.11627&volume=93&issue=2&pages=295-298&publication_year=2008&author=Wechalekar%2CAD&author=Lachmann%2CHJ&author=Offer%2CM&author=Hawkins%2CPN&author=Gillmore%2CJD
- How much cash flow does https://link.springer.com/doi/10.1007/s00277-010-1062-6 have monthly?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3MXkt1Cisg%3D%3D bring in each month?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20821326
- http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20the%20combination%20of%20bortezomib%20and%20dexamethasone%20in%20systemic%20AL%20amyloidosis&journal=Ann%20Hematol.&doi=10.1007%2Fs00277-010-1062-6&volume=90&issue=2&pages=201-206&publication_year=2011&author=Lamm%2CW&author=Willenbacher%2CW&author=Lang%2CA&author=Zojer%2CN&author=M%C3%BCld%C3%BCr%2CE&author=Ludwig%2CH's financial summary
- Discover the revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38Xnt1Gktr8%3D
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22331188?
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557400 generate?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Cyclophosphamide-bortezomib-dexamethasone%20%28CyBorD%29%20produces%20rapid%20and%20complete%20hematologic%20response%20in%20patients%20with%20AL%20amyloidosis&journal=Blood.&doi=10.1182%2Fblood-2011-11-390930&volume=119&issue=19&pages=4391-4394&publication_year=2012&author=Mikhael%2CJR&author=Schuster%2CSR&author=Jimenez-Zepeda%2CVH&author=Bello%2CN&author=Spong%2CJ&author=Reeder%2CCB generate?
- What is the monthly revenue of https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC38Xnt1Gksbc%3D?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22331187
- Revenue of http://scholar.google.com/scholar_lookup?&title=Cyclophosphamide%2C%20bortezomib%2C%20and%20dexamethasone%20therapy%20in%20AL%20amyloidosis%20is%20associated%20with%20high%20clonal%20response%20rates%20and%20prolonged%20progression-free%20survival&journal=Blood.&doi=10.1182%2Fblood-2011-10-388462&volume=119&issue=19&pages=4387-4390&publication_year=2012&author=Venner%2CCP&author=Lane%2CT&author=Foard%2CD&author=Rannigan%2CL&author=Gibbs%2CSD&author=Pinney%2CJH
- Get to know https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtVyiur3N's earnings
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19498019?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Weekly%20and%20twice-weekly%20bortezomib%20in%20patients%20with%20systemic%20AL%20amyloidosis%3A%20results%20of%20a%20phase%201%20dose-escalation%20study&journal=Blood.&doi=10.1182%2Fblood-2009-02-203398&volume=114&issue=8&pages=1489-1497&publication_year=2009&author=Reece%2CDE&author=Sanchorawala%2CV&author=Hegenbart%2CU&author=Merlini%2CG&author=Palladini%2CG&author=Fermand%2CJP is on a monthly basis
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtFaitrrO rake in every month?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19506160
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727288 earn?
- What's the income of http://scholar.google.com/scholar_lookup?&title=Primary%20therapy%20of%20Waldenstr%C3%B6m%20macroglobulinemia%20with%20bortezomib%2C%20dexamethasone%2C%20and%20rituximab%3A%20WMCTG%20clinical%20trial%2005-180&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2008.20.4677&volume=27&issue=23&pages=3830-3835&publication_year=2009&author=Treon%2CSP&author=Ioakimidis%2CL&author=Soumerai%2CJD&author=Patterson%2CCJ&author=Sheehy%2CP&author=Nelson%2CM?
- How much profit does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD2sXlsVynuro%3D generate?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17353550 each month?
- http://scholar.google.com/scholar_lookup?&title=Bortezomib%20is%20active%20in%20patients%20with%20untreated%20or%20relapsed%20Waldenstrom%E2%80%99s%20macroglobulinemia%3A%20a%20phase%20II%20study%20of%20the%20National%20Cancer%20Institute%20of%20Canada%20Clinical%20Trials%20Group&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2006.07.8659&volume=25&issue=12&pages=1570-1575&publication_year=2007&author=Chen%2CCI&author=Kouroukis%2CCT&author=White%2CD&author=Voralia%2CM&author=Stadtmauer%2CE&author=Stewart%2CAK's total income per month
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3cXht1Sqtb7P generate monthly?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20652865 earning monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Phase%20II%20trial%20of%20weekly%20bortezomib%20in%20combination%20with%20rituximab%20in%20untreated%20patients%20with%20Waldenstr%C3%B6m%20macroglobulinemia&journal=Am%20J%20Hematol.&doi=10.1002%2Fajh.21788&volume=85&issue=9&pages=670-674&publication_year=2010&author=Ghobrial%2CIM&author=Xie%2CW&author=Padmanabhan%2CS&author=Badros%2CA&author=Rourke%2CM&author=Leduc%2CR generate monthly?
- How profitable is https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BC3sXhslyqtL7N?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24004667's total income per month
- How profitable is http://scholar.google.com/scholar_lookup?&title=Primary%20therapy%20of%20Waldenstrom%20macroglobulinemia%20%28WM%29%20with%20weekly%20bortezomib%2C%20low-dose%20dexamethasone%2C%20and%20rituximab%20%28BDR%29%3A%20long-term%20results%20of%20a%20phase%202%20study%20of%20the%20European%20Myeloma%20Network%20%28EMN%29&journal=Blood.&doi=10.1182%2Fblood-2013-05-503862&volume=122&issue=19&pages=3276-3282&publication_year=2013&author=Dimopoulos%2CMA&author=Garc%C3%ADa-Sanz%2CR&author=Gavriatopoulou%2CM&author=Morel%2CP&author=Kyrtsonis%2CMC&author=Michalis%2CE?
- How much income is https://link.springer.com/article/10.1007/s40262-018-0679-9/articles/cas-redirect/1:CAS:528:DC%2BD28XnslKhs7c%3D earning monthly?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16754936 generate?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Frequency%2C%20characteristics%2C%20and%20reversibility%20of%20peripheral%20neuropathy%20during%20treatment%20of%20advanced%20multiple%20myeloma%20with%20bortezomib&journal=J%20Clin%20Oncol.&doi=10.1200%2FJCO.2005.04.7779&volume=24&issue=19&pages=3113-3120&publication_year=2006&author=Richardson%2CPG&author=Briemberg%2CH&author=Jagannath%2CS&author=Wen%2CPY&author=Barlogie%2CB&author=Berenson%2CJ is on a monthly basis
- Learn how profitable https://citation-needed.springer.com/v2/references/10.1007/s40262-018-0679-9?format=refman&flavour=references is on a monthly basis
- Profit of https://link.springer.com/article/10.1007/s40262-018-0679-9/search?sortBy=newestFirst&dc.creator=Carlyn%20Rose%20C.%20Tan
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carlyn%20Rose%20C.%20Tan?
- What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carlyn%20Rose%20C.%20Tan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://link.springer.com/article/10.1007/s40262-018-0679-9/search?sortBy=newestFirst&dc.creator=Saif%20Abdul-Majeed's financial summary
- What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Saif%20Abdul-Majeed?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Saif%20Abdul-Majeed%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earn?
- Income figures for https://link.springer.com/article/10.1007/s40262-018-0679-9/search?sortBy=newestFirst&dc.creator=Brittany%20Cael
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brittany%20Cael rake in every month?
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brittany%20Cael%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://link.springer.com/article/10.1007/s40262-018-0679-9/search?sortBy=newestFirst&dc.creator=Stefan%20K.%20Barta generate monthly?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stefan%20K.%20Barta generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stefan%20K.%20Barta%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
- How much profit does https://link.springer.com/article/10.1007/s40262-018-0679-9/mailto:[email protected] generate?
- Learn about the earnings of https://s100.copyright.com/AppDispatchServlet?title=Clinical%20Pharmacokinetics%20and%20Pharmacodynamics%20of%20Bortezomib&author=Carlyn%20Rose%20C.%20Tan%20et%20al&contentID=10.1007%2Fs40262-018-0679-9©right=Springer%20International%20Publishing%20AG%2C%20part%20of%20Springer%20Nature&publication=0312-5963&publicationDate=2018-05-26&publisherName=SpringerNature&orderBeanReset=true
- What's the profit of https://crossmark.crossref.org/dialog/?doi=10.1007/s40262-018-0679-9?
- How much does https://citation-needed.springer.com/v2/references/10.1007/s40262-018-0679-9?format=refman&flavour=citation make?
- What's https://link.springer.com/journals/a/1's gross income?
- What is the earnings of https://link.springer.com/books/a/1?
- Learn how profitable https://link.springer.com/journals is on a monthly basis
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral rake in every month?
- What's the total monthly financial gain of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- How much does https://www.springernature.com/gp/products make?
- What are the total earnings of https://www.springernature.com/gp/librarians?
- How much does https://www.springernature.com/gp/societies rake in every month?
- How much does https://www.springernature.com/gp/partners pull in monthly?
- What's the financial outcome of https://www.springer.com/?
- What's the monthly income of https://www.nature.com/?
- What is the earnings of https://www.biomedcentral.com/?
- How profitable is https://www.palgrave.com/?
- What's the monthly income of https://www.apress.com/?
- What's the profit of https://link.springer.com/brands/discover?
- How much does https://www.springernature.com/gp/legal/ccpa rake in every month?
- Revenue of https://www.springernature.com/gp/info/accessibility
- How much cash flow does https://link.springer.com/termsandconditions have monthly?
- https://support.springernature.com/en/support/home's revenue stream
- How much profit is https://link.springer.com/legal-notice making per month?
- Income figures for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
- Find out how much https://www.springernature.com/ earns monthly
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
Emails and Hosting {✉️}
Mail Servers:
- mx.zoho.eu
- mx2.zoho.eu
- mx3.zoho.eu
Name Servers:
- josh.ns.cloudflare.com
- zita.ns.cloudflare.com
CDN Services {📦}
- Crossref